ScholarX: NAM, SEOK JIN

Detailed Information

NAM, SEOK JIN (남석진)

Medicine (Medicine)

Research Area

Tel 02-3410-3901
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Breast neoplasms:63||Breast cancer:51||breast cancer:37||Prognosis:26||Breast neoplasm:19||Breast:13||Neoadjuvant chemotherapy:13||Sentinel lymph node biopsy:11||Recurrence:10||Triplenegative breast cancer:9||Chemotherapy:9||triplenegative breast cancer:9||BRCA1:9||neoadjuvant chemotherapy:9||Immunohistochemistry:9||BRCA2:8||MMP9:8||Survival:8||breast neoplasm:7||survival:7||HER2:7||Silibinin:6||Berberine:6||Estrogen receptor:6||Korea:5||Quality of life:5||Breast Neoplasms:5||Radiotherapy:5||Lymphatic metastasis:5||Cell invasion:5||Neoadjuvant therapy:5||recurrence:4||Sentinel lymph node:4||breast:4||quality of life:4||Lymph nodes:4||Axilla:4||Ductal carcinoma in situ:4||Breast cancer survivors:4||Mutation:4||Young breast cancer:4||Treatment outcome:4||Metastasis:4||Nomograms:4||Breast reconstruction:4||Tamoxifen:4||Pathologic complete response:4||Triple negative breast neoplasms:3||Neoadjuvant Therapy:3||Validation:3||Male:3||breast neoplasms:3||Neoadjuvant:3||Lymph node excision:3||Return to work:3||Survivorship:3||Human epidermal growth factor receptor 2:3||axillary lymph node dissection:3||radiotherapy:3||triple negative breast cancer:3||BRCA mutation:3||Magnetic resonance imaging:3||casecontrol study:3||ErbB2:3||MRI:3||ErbB2 receptor:3||TNBC:3||Incidence:3||EGFR:3||silibinin:3||PDOX:3||HER2positive breast cancer:3||Registries:3||STAT3:3||Hormone receptor:3||patientderived orthotopic xenograft:3||menopausal status:3||Mastectomy:3||trastuzumab resistance:2||HER2negative:2||Intrinsic subtype:2||Body image:2||TGFbeta 1:2||Metabolomics:2||Methylation:2||hormone receptor:2||zerumbone:2||Tamoxifen resistance:2||<:2||Axillary arch:2||Prognostic factor:2||Health behavior:2||Ki67:2||Mortality:2||Treatment:2||Health knowledge:2||BRCA2 gene mutation:2||Fibronectin:2||Education:2||Hepatocellular carcinoma:2||machine learning:2||Emigrants and immigrants:2||mammography:2||Tumorinfiltrating lymphocytes:2||Hereditary:2||Liver cirrhosis:2||Lobular carcinoma:2||metastasis:2||metastatic breast cancer:2||Xenograft:2||Follicular lymphoma:2||Radiation therapy:2||Zerumbone:2||Neoadjuvant treatment:2||Hereditary breast and ovarian cancer syndrome:2||Neoplasm metastasis:2||Local recurrence:2||Neoplasms:2||CD44:2||Nipplesparing mastectomy:2||neoadjuvant endocrine therapy:2||Nomogram:2||neoplasm:2||Receptor:2||Clinical characteristics:2||Breast Cancer:2||Lymph node:2||oncologic outcomes:2||oncology:2||Adjuvant radiotherapy:2||p53:2||Oncology:2||pathologic complete response:2||Cancer:2||poor prognosis:2||Lymphoscintigraphy:2||Cancer survivors:2||Carcinoma:2||chemotherapy:2||IL8:2||progesterone receptor:2||prognosis:2||prognostic factor:2||MMP2:2||PLSDA:2||Segmental mastectomy:2||Machine learning:2||residual cancer burden:2||Goserelin:2||Silybum marianum:2||Mammaplasty:2||sentinel lymph node:2||sentinel lymph node biopsy:2||Phosphatidylinositol 3kinases:2||Social support:2||Drug therapy:2||Mass screening:2||surgery:2||Subcutaneous mastectomy:2||surveillance:2||survivorship:2||Aged:2||tamoxifen:2||HER2low:2||thyroid cancer:2||Survival outcome:2||Frozen section analysis:1||Frozen sections:1||Gamma cameras:1||Gamma probe:1||Ganglioneuroma:1||Genes:1||GenesWell BCT assay:1||Genetic:1||Genetic counseling:1||Genomics:1||Gim:1||GnRH:1||Gonadotropinreleasing hormone:1||Gonadotropinreleasing hormone Agonist:1||Granulomatous mastitis:1||HER2:1||HER2 positivity:1||HER2 protein:1||HER2+ breast cancer:1||HER2+breast cancer:1||HER2overexpressing breast cancer:1||HER2positive (HR/HER2+) breast cancer:1||HER2/neu discordance:1||HER3:1||HLADR Antigens:1||HPV DNA chip typing:1||HR+/HER2early breast cancer:1||HSP90:1||Healthrelated quality of life:1||Healthrelated quality of life (HRQoL):1||Healthcare providers:1||Her2:1||Hereditary breast:1||Hereditary breast cancer:1||Hereditary breast neoplasm:1||Hereditary neoplastic syndromes:1||Heterozygot:1||Hormone antagonists:1||Hormone receptor negative:1||Hormone receptorpositive breast cancer:1||IL1:1||IL1 beta:1||IL1β IL8:1||IL6:1||Ileum:1||Immune gene signature:1||Immune responserelated genes (igenes):1||Immune subtypes:1||Immunohistoch:1||Implant capsular contracture:1||Incidental findings:1||Indocyanine green:1||Induction chemotherapy:1||Inflammation:1||Insurance:1||Integrin:1||Intervention:1||Intracystic papillary carcinoma:1||Intramammary lymph node:1||Invasion:1||Invasive:1||Invasive ductal breast cancer:1||Invasive ductal carcinoma:1||Invasive micropapillary carcinoma:1||Ipsilateral breast cancer recurrence:1||Ipsilateral breast tumor recurrence:1||Ischaemic time:1||Isoflavones:1||JAKs:1||Ki67 proliferation index:1||Korean:1||Korean national insurance coverage:1||Korean women:1||Laparoscopy:1||Latissimus dorsi flap (LD flap):1||Letrozole:1||Local Recurrence:1||Local neoplasm recurrence:1||Localization:1||Locoregional neoplasm recurrence:1||Luminal breast cancer:1||Lymph no:1||Lymph node ratio:1||Lymphatic:1||Lymphatic Metastasis:1||Lymphatic irradiations:1||Lymphedema:1||Lymphovascular invasion:1||Lysosome:1||MCF7 human breast cancer cells:1||MEK:1||MEK/ERK pathway:1||METTL18:1||MIB1:1||MMP1:1||MMP3:1||MMPs:1||Male breast cancer:1||Malignant melanoma:1||Mammographic density:1||Mammography:1||Mammoplasty:1||Manganese:1||Margins of Excision:1||Marital status:1||Mastectomy, Segmental:1||Mastectomy, Simple:1||Matrix metalloproteinase9 (MMP9):1||Medullary carcinoma:1||Menstrual cycle:1||Menstruation:1||Methylene blue:1||Methylene blue dye:1||Microcalcification:1||Missense mutation:1||Mitogenactivated protein kinase kinase:1||Miyeok:1||Mobile health:1||Molecular diagnostic techniques:1||Molecular subtype:1||Molybdenum:1||Mucinous:1||Musclesparing la:1||Myelolipoma:1||N3:1||NBS1:1||NFB:1||NFkappa B:1||Neoadjuvant TCHP regimen:1||Neoadjuvant endocrine therapy:1||Neoadjuvant stusdy of chemotherapy versus Endocrine therapy in premenopausal patient with hormone responsive:1||Neoadjuvant systemic therapy:1||Neoplasm metastasi:1||Neoplasm staging:1||Nerve growth factor:1||NodePositive Breast Cancer:1||OCR:1||Obesity:1||Objective measured:1||Older patients:1||Oligonucleotide therapy:1||Oncologic outcomes:1||Online system:1||Online systems:1||Ovarian cancer:1||Ovarian cancer syndrome:1||Ovarian function:1||Ovarian function suppression:1||Ovarian neoplasm:1||Ovarian neoplasms:1||Ovarian suppression:1||Overall survival:1||P53:1||PDGFRA:1||PDX:1||PET CT:1||PI3K:1||PKCalpha:1||PSCAD/EMTDC:1||Paget disease:1||Papillomavirus, human:1||Patient reported outcome:1||Patientreported outcome (PRO):1||Patterns of failure:1||Pedometer:1||Penetrance of BRCA mutation:1||Perioperative period:1||Phyllodes tumor:1||Physical activity:1||Pifithrinalpha:1||Poloxamer:1||Population characteristics:1||Port insertion site recurrence:1||Postmastectomy radiation therapy:1||Postmenopause:1||Postoperative complications:1||Postoperative period:1||Postoperative radiotherapy:1||Premenopausal women:1||Prediction:1||Pregnancy:1||Pregnancy rate:1||Premenopausal:1||Premenopause:1||Preoperative imaging:1||Prevention:1||Primary systemic therapy:1||Professional education:1||Progesterone receptor:1||Progesterone receptors:1||Progn:1||Prognostic biomarker:1||Prognostic factors:1||Prognostic group:1||Prognostic markers:1||Prognostic model:1||Program development:1||Program evaluation:1||Proliferationrelated genes (pgenes):1||Prophylactic Mastectomy:1||Proportion:1||Prospective cohort study:1||Proteasome:1||Psychosocial support:1||Pure mucinous adenocarcinoma:1||QoL:1||RNAi:1||RPL3 methylation:1||Rad:1||Radiation dose hypofractionation:1||Radiation injuries:1||Radiationinduced neoplasms:1||Radioisotope:1||Radiologic complete response:1||Radiotherapy Recurren:1||Randomized controlled trials:1||Rare benign adrenal tumor:1||Ratio:1||Reentry period:1||Real world evidence:1||Receptors, estrogen:1||Recombinant methioninase:1||Reconstruction methods:1||Recurr:1||Recurrencefree survival:1||Regional:1||Relapse pattern:1||Relapsefree survival:1||Reliability:1||Reproductive factors:1||Res:1||Response:1||Risk:1||Risk of distant metastasis:1||SATSF:1||SKBR3 cells:1||STAT3:1||STAT1:1||SUSD2:1||Salpingoovariectomy:1||Schwannoma:1||Scott transformer:1||Screendetected:1||Seaweed:1||Secondary partial mastectomy:1||Segmental:1||Selfmanagement:1||Sensitivity:1||Sentine:1||Sentinel Lymph Node Biopsy:1||Sentinel lymph node biopy:1||Serial body weight change:1||Short form development:1||Shoulder:1||Silicone:1||Skinsparing mastectomy:1||Smad3:1||Somatic mutations:1||Somatoform disorders:1||Sonography:1||Src kinase:1||Stigma:1||Strategy:1||Subcutaneous Mastectomy:1||Supraclavicular recurrence:1||Surgery:1||Surgical staplers:1||Surgical wound infection:1||T1 stage:1||TCHP:1||TGFbeta:1||TGFbeta 2:1||TGFα:1||TIMP:1||TNFalpha:1||TNM stage:1||TNM staging:1||TP53:1||TPA:1||TWIST1:1||Taxane:1||Technetium 99m Sestamibi:1||Telemedicine:1||Tissue expansion devices:1||Trace elements:1||Transcription factor AP1:1||Trastuzumab:1||Triple negative:1||Triple negative breast cancer:1||Triple negative breast cancer (TNBC):1||Triplenegative Breast Neoplasms:1||Triplenegative breast neoplasms:1||Tubular:1||Tumor burden:1||Tumor suppressor protein p53:1||Urine:1||VEGF:1||Validation study:1||Vascular endothelial growth factor (VEGF):1||Volumetry:1||WNT5A:1||Workrelated difficulties:1||Young:1||Young adult:1||Young women:1||actin:1||adjuvant cohort:1||adjuvant endocrine therapy:1||algorithm:1||altered appearance distress:1||anchorageindependent growth:1||angiosarcoma:1||apoptosis:1||ascites:1||b:1||benign phyllodes tumo:1||berberine:1||biopsy biopsies:1||body
image:1||body weight:1||bone metastasis:1||brain metastasis:1||breast angiosarcoma:1||breast biopsy:1||breast cancer survivor:1||breast cancerspecific survival:1||breast carcinoma:1||breast conserving surgery:1||breast metastasis:1||calcitriol:1||cancer:1||cancer care:1||carbohydrate:1||carcinoma:1||celastrol:1||cell invasion:1||central neck dissection:1||cholecalciferol:1||cholesterol:1||circadian rhythm:1||circulating tumor DNA:1||clinical relevance:1||coaching:1||collagen type I:1||conditional survival:1||consensus recommendations:1||copy number variation:1||core needle biopsy:1||cytokine:1||dermatofibrosarcoma protuberans:1||develop:1||diagnosis:1||diagnostic value:1||disease free survival:1||diseasefree survival:1||diseasefree survivor:1||distress management:1||drug monitoring:1||employment:1||endocrine symptoms:1||endocrine therapy:1||endoscopic thyroidectomy:1||epidemiology:1||epidermal growth factor receptor:1||escalated treatment:1||estrogen receptor:1||excision:1||exosomes:1||expression assay:1||extracellular vesicles:1||false negative rates:1||falsenegative rate:1||fibroblast:1||fibronectin:1||gastric cancer:1||gene:1||genetic counseling:1||genetic counselor:1||genotype:1||glycemic index:1||glycemic load:1||happiness:1||healthrelated quality of life:1||hereditary breast and ovarian cancer syndrome:1||heregulinb:1||histidine methyltransferase:1||hope:1||hormone receptor status:1||hormone receptorpositive breast cancer:1||hormone replacement therapy:1||human:1||indocyanine green:1||indocyanine green (ICG):1||inhibitor:1||insurance coverage expansion:1||interleukin 1&#946:1||interleukin 8:1||interleukin10:1||intraductal:1||invasion:1||invasive ductal carcinoma:1||isosulfan blue:1||late distant recurrence:1||lipids:1||liver metastasis:1||localization:1||luminal A breast cancer:1||lung metastasis:1||lymph node:1||lymph nodepositive breaST (NEST):1||lymph nodepositive breaST cancer (NEST):1||lymphocytes:1||macrophages:1||mastectomy:1||matrix metalloproteinase 1:1||matrix metalloproteinase 9:1||matrix metalloproteinases:1||mechanism:1||menopause:1||metabolite:1||metachronous second primary neoplasm:1||metaplastic breast cancer:1||metastatic thymoma:1||methylene blue:1||microRNA145:1||micrometastasis:1||migration:1||model:1||molecular subtypes:1||multifactorial probabilitybased analysis:1||multiple tumors:1||mushrooms:1||mutation:1||nCounter mRNA expression assay:1||neoadjuvant chemotherapy:1||neoadjuvant chemotherapy (NAC):1||neoadjuvant study of chemotherapy versus Endocrine therapy in premenopausal patient with hormone responsive:1||neoadjuvant therapy:1||neoadjvant chemotherapy:1||neoplasms, multiple primary:1||neuronal apoptosis inhibitory protein (NAIP):1||nodepositive breast cancer:1||nonpalpable:1||noninfiltrating:1||nonpalpable lesions breast:1||number of lymph nodes:1||oral calcium:1||oral recombinant methioninase:1||overall survival:1||p16:1||p21:1||papillary lesion:1||pathologic complete response (pCR):1||patientderived xenograft:1||patientreported outcome:1||patientreported outcomes:1||pertuzumab:1||phorbol ester:1||physical activity:1||plateletderived growth factor beta:1||postmastectomy radiotherapy:1||predict:1||prediction model:1||predictive value:1||pregnancy:1||premenopausal:1||premenopausal patients:1||primary angiosarcoma of the breast:1||primary sarcoma:1||prognostic biomarker:1||prognostic value:1||propensity score:1||prospective cohort:1||psychooncology:1||purpose in life:1||quality:1||radiationinduced dermatitis:1||remetastasis:1||real time prediction:1||realtime quantitative polymerase chain reaction:1||recurrence model:1||recurrent thymoma:1||reentry period:1||refractory:1||resection:1||residual proliferative cancer burden:1||retroperitoneal tumors:1||rice:1||risk factor:1||routine followup:1||secondary:1||sentinel lymph node localization:1||single nucleotide variant:1||skin toxicity:1||social stigma:1||socioeconomic status:1||sonography:1||soy foods:1||stage IV breast cancer:1||stanniocalcin1:1||surgical excision:1||survivor:1||suspicious palpable lymph node biopsy:1||tamoxifenresistant breast cancer:1||targeted exome sequencing:1||technology:1||total thyroidectomy:1||trajectory:1||treatment:1||triple negative:1||triple negative breast neoplasm:1||triplenegative breast neoplasm:1||trocar site recurrence:1||tumor response:1||tumorInfiltrating:1||vacuum biopsy:1||variants of uncertain significance:1||variation:1||vascular endothelial growth factor A:1||young breast cancer patients:1||ΑSMA:1||골수지방종:1||부신 희귀 양성종양:1||부신낭종:1||신경수초종:1||신경절신경종:1||12Otetradecanoyl phorbol13acetate (TPA):1||= 1 cm Invasive breast cancer:1||= 1 cm i:1||A proliferationinducing ligand:1||ABO blood type:1||ACMG standards and guidelines:1||ACTA2:1||AJCC 8th edition:1||AKT:1||ALDH:1||AP1:1||APOBEC3B germline deletion:1||ASCO/CAP guidelines:1||Absorbable implants:1||Adenovirus:1||Adenocarcinoma:1||Adjuvant chemotherapy:1||Adjuvant endocrine therapy:1||Adjuvant treatment:1||Adrenal cyst:1||Akt:1||Alopecia:1||Alopecia distress scale:1||Altered appearance:1||AmpliSeq:1||AntiHER2 targeted therapy:1||Anticipation:1||Anxiety:1||Appearance:1||Aromatase inhibitorassociat:1||Aromatase inhibitors:1||Asia:1||Asian:1||At feeding system:1||Atypical ductal hyperplasia:1||Axillary:1||Axillary lymph node:1||Axillary lymph node dissection:1||Axillary lymph node dissections:1||Axillary pathologic complete response:1||Axillary surgery:1||BCT score:1||BIRADS category 3 masses:1||BRCA 1/2:1||BRCA genes:1||BRCA1 gene:1||BRCA1/2 mutation:1||BRCA2 gene:1||BRIP1:1||Bilateral mastectomy:1||Biology:1||Biomarker:1||Bmi1:1||Body mass index:1||Bone:1||Bre:1||Breast MRI:1||Breast Neoplasm:1||Breast Reconstruction:1||Breast cancer metastasis:1||Breast cancer surgery:1||Breast conserving surgery:1||Breast neoplams:1||Breastconserving surgery:1||CXC motif chemokine ligand 13:1||CD163 protein:1||CSIHC4:1||CTS5:1||CXCL8:1||Cancer survivor guidelines:1||Carcinoma, Intraductal, Noninfiltrating:1||Cardiotoxicity:1||Casecontrol studies:1||Casecontrol study:1||Cdc2:1||Cell adhesion:1||Cell cycle regulator:1||Cell migration:1||Cervical cancer:1||Change:1||Chemotherapy, Adjuvant:1||Chemotherapyinduced alopecia:1||Chemotherapyinduced skin change:1||Chip:1||Chronological change:1||Classification:1||Clinical outcome:1||Clinical practice patterns:1||Clinical response:1||Cohort:1||Cohort profile:1||Cohort study:1||Collagen:1||Combined mo:1||Comparison:1||Complete Response:1||Complete response:1||Computed Tomography:1||Contralateral sentinel lymph node biopsy:1||Core needle biopsy Estrogen receptors:1||Cosmetic:1||Costs and cost analysis:1||Cyclin B1:1||Cyclooxygenase2:1||CytologyProven:1||Cytologyproven axillary metastasis:1||DIEP flap:1||DNA methylation:1||DNA repair pathway:1||Deep inferior epigas:1||Depression:1||Dermal:1||Diagnosis:1||Differential:1||Differentiated thyroid cancer (DTC):1||Diffuse large Bcell lymphoma:1||Diffusionweighted imaging:1||Dissection:1||Distress:1||Divorce:1||Double heterozygosity:1||Dryness:1||Dullness:1||Dyslipidemia:1||E2:1||EGF:1||EGFR+HER2+:1||ER status:1||ERhigh:1||ERlow:1||ERK:1||Early detection of cancer:1||Early failure:1||Employment:1||Endocrine therapy:1||Endoscopic thyroidectomy:1||Endoxifen:1||Entelon:1||Epidemiology:1||Epithelialmesenchymal transition:1||Equivocal:1||Eribulin:1||Estrogen receptors:1||Ethnic groups:1||Excisio:1||Exercise:1||Existential wellbeing:1||Exosomes:1||Extracellular signalregulated kinase:1||Extracellular vesicles:1||FDG PET:1||FISH:1||FSH:1||Familial:1||Familial cancer:1||Family history:1||Fat necrosis:1||Feasibility:1||Female:1||Fertility:1||Fibrin:1||Fibronectins:1||Financial stress:1||Follicular neoplasm:1||Follicular thyroid carcinoma:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE